Deciphera Pharmaceuticals LLC

Deciphera Pharmaceuticals — CTOS Annual Meeting 2020

14 slides from Deciphera Pharmaceuticals's conference presentation, Nov 12, 2020

  1. Slide 1: Phase 1 Dose-Escalation Study of DCC-3014 in Advanced Solid Tumors and TGCT

    Exhibit 99.1 CTOS Annual Meeting, Nov 18–21, 2020 Phase 1 Dose-Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DCC-3014 in Advanced Solid Tumors and Tenosynovial Giant Cell Tumor (TGCT) (NCT3069469) Albiruni Abdul Razak1, Breelyn A. Wilky2, Jacqueline Vuky3, L

  2. Slide 2: Disclosures

    CTOS Annual Meeting, Nov 18–21, 2020 Disclosures Albiruni R. Abdul Razak • Honoraria: Boehringer Ingelheim • Consulting or Advisory Role: Eli Lilly, Merck, Boehringer Ingelheim, Adaptimmune • Research Funding: CASI Pharmaceuticals, Boehringer Ingelheim, Lilly, Novartis, Deciphera, Karyopharm Therape

  3. Slide 3: DCC-3014 – Highly Selective CSF1R Kinase Inhibitor

    CTOS Annual Meeting, Nov 18–21, 2020 DCC-3014 – Highly Selective CSF1R Kinase Inhibitor CSF1R • DCC-3014 is a highly selective, oral, FGFR4 CSF1R FGFR1 investigational switch control kinase FLT1 VEGFR2 inhibitor that exhibits nanomolar KIT RET MER potency for CSF1R with >100-fold AXL SKY FLT4 FLT3PD

  4. Slide 4: Study Design

    CTOS Annual Meeting, Nov 18–21, 2020 Study Design Phase 2 Expansion Phase 1 Cohort A Dose escalation n ~40 pts (3+3 design) Declare TGCT No prior anti-CSF1/CSF1R n ~60 pts RP2D MST and TGCT Expansion Cohort B Symptomatic TGCT not amenable to surgery n ~20 pts TGCT Prior anti-CSF1/CSF1R allowed Phase

  5. Slide 5: Phase 1 Enrollment and Patient Disposition

    CTOS Annual Meeting, Nov 18–21, 2020 Phase 1 Enrollment and Patient Disposition • Study initially enrolled patients with malignant solid tumors in the first 7 cohorts • TGCT patients initially enrolled to escalation cohort 5, then TGCT-specific escalation cohorts 8 and 9 were enrolled Enrollment MST

  6. Slide 6: TGCT Patient Demographics and Prior Therapies

    CTOS Annual Meeting, Nov 18–21, 2020 TGCT Patient Demographics and Prior Therapies Total (N = 25) Age, years, median (min, max) 52 (23, 73) Gender Female 14 (56) Male 11 (44) Race White 24 (96) Asian 1 (4) Disease location Knee 16 (64) Ankle 5 (20) Hip 2 (8) Foot 1 (4) Wrist 1 (4) Patients with at l

  7. Slide 7: Common TEAEs, Regardless of Relatedness – TGCT Safety Population

    CTOS Annual Meeting, Nov 18–21, 2020 Common ( ³ 15%) TEAEs, Regardless of Relatedness – TGCT Safety Population TGCT patients (N = 25) • Observed transaminase and pancreatic Cohort 5 Cohort 8 Cohort 9 Total TGCT Preferred term, No. (%) 30 mg BIWa 10 mg QDb 6 mg QDc enzyme elevations are consistent wi

  8. Slide 8: Dose Modifications Due to Adverse Events

    CTOS Annual Meeting, Nov 18–21, 2020 Dose Modifications Due to Adverse Events Cohort 5 Cohort 8 Cohort 9 30 mg BIWa 10 mg QDb 6 mg QDc Total (N = 7) (N = 12) (N = 6) (N = 25) Patients with TEAE leading to dose modification, 3 (43) 5 (42) 1 (16.7) 9 (36) No. (%) Dose interruption 3 (43) 5 (42) 1 (16.

  9. Slide 9: DCC-3014 Pharmacokinetics and Pharmacodynamics

    CTOS Annual Meeting, Nov 18–21, 2020 DCC-3014 Pharmacokinetics and Pharmacodynamics • Steady state DCC-3014 exposure in TGCT patients Repeat dose DCC-3014 at cohorts 5, 8, and 9 was characterized concentration-time profile, cycle 2 day 1 • Cohorts 5 and 8 had similar PK at cycle 2, day 1 1500 Cohort

  10. Slide 10: Antitumor Activity in TGCT Patients

    CTOS Annual Meeting, Nov 18–21, 2020 Antitumor Activity in TGCT Patients • Of the 25 TGCT patients enrolled into the study, 22 patients were evaluable for efficacy by RECIST v1.1 at the data cut off • 21 patients had central assessment for efficacy • 1 patient had local assessment for efficacy but n

  11. Slide 11: TGCT Case Studies

    CTOS Annual Meeting, Nov 18–21, 2020 TGCT Case Studies Case Study 1 • 57-year-old female diagnosed with TGCT (hip) in 2014 67% ↓ • Prior surgeries: • Resection (May 2014) • Synovectomy (August 2015, August 2016) • Resection and total hip replacement (August 2018) • Cryoablation (May 2019) • Baseli

  12. Slide 12: TGCT Case Studies

    CTOS Annual Meeting, Nov 18–21, 2020 TGCT Case Studies Case Study 2 41% ↓ • 39-year-old female diagnosed with TGCT (knee) in April 2020 • No prior systemic therapy or surgery • Baseline tumor burden: 126 mm • Enrolled in June 2020 (cohort 8 – DCC-3014 10 mg daily) • Partial response after 2 cycles

  13. Slide 13: Conclusions

    CTOS Annual Meeting, Nov 18–21, 2020 Conclusions • DCC-3014 is a highly selective, oral, investigational switch control kinase inhibitor of CSF1R and is generally well tolerated in patients with TGCT not amenable to surgery • 22 of the 25 TGCT patients remain on the study • Similar steady state PK p

  14. Slide 14: Acknowledgements

    CTOS Annual Meeting, Nov 18–21, 2020 Acknowledgements • The authors would like to thank the patients and their families and caregivers, the investigators, and the investigational site staff of this study • This study was sponsored by Deciphera Pharmaceuticals, LLC, Waltham, MA, USA • Editorial assis

Deciphera Pharmaceuticals — CTOS Annual Meeting 2020 on 6ix